CNS Pharmaceuticals Inc (CNSP)
0.116
+0.01
(+4.60%)
USD |
NASDAQ |
Jan 08, 16:00
0.11
-0.01
(-5.17%)
Pre-Market: 08:33
CNS Pharmaceuticals SG&A Expense (Quarterly): 1.384M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 24.48M |
| Cellectar Biosciences Inc | 7.834M |
| Revance Therapeutics Inc | 62.22M |
| Zymeworks Inc | 13.90M |
| NovaBay Pharmaceuticals Inc | 2.65M |